Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154722 | 0.83 | LTA4H (0.37) | CYP2D6LTA4HKCNA3NPC1RAB9A | |
| SCHEMBL3154778 | 0.81 | NPC1 (0.35) | NPC1RAB9A | |
| SCHEMBL3174110 | 0.80 | KCNA3 (0.31) | KCNA3 | |
| SCHEMBL10785918 | 0.75 | KCNA3 (0.43) | KCNA3 | |
| SCHEMBL3163510 | 0.74 | LTA4H (0.58) | CYP2D6LTA4HCYP3A4NPC1RAB9A | |
| SCHEMBL182812 | 0.71 | CYP2D6 (0.41) | CYP2D6LTA4HCYP3A4 | |
| SCHEMBL27448379 | 0.70 | KCNA3 (0.41) | LTA4HKCNA3 | |
| SCHEMBL832700 | 0.69 | NPC1 (0.61) | LTA4HKCNA3NPC1RAB9A | |
| SCHEMBL3165235 | 0.69 | CYP2D6 (0.49) | CYP2D6LTA4HCYP3A4 | |
| SCHEMBL3169037 | 0.69 | CYP3A4 (0.54) | CYP2D6LTA4HCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1809570-B | [1,2,4] triazolo [1,5-a ] pyrimidin-2-ylurea derivatives and uses thereof | NIPPON KAYAKU KK | 2011-06-22 | — | — | CN | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1630165-A1 | [1,2,4 ]TRIAZOLO [1,5-A]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | CYP2D6 1505/4885LTA4H 461/4885KCNA3 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.